325 related articles for article (PubMed ID: 30422115)
21. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
[TBL] [Abstract][Full Text] [Related]
22. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
23. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
24. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
Kwiatkowski N; Zhang T; Rahl PB; Abraham BJ; Reddy J; Ficarro SB; Dastur A; Amzallag A; Ramaswamy S; Tesar B; Jenkins CE; Hannett NM; McMillin D; Sanda T; Sim T; Kim ND; Look T; Mitsiades CS; Weng AP; Brown JR; Benes CH; Marto JA; Young RA; Gray NS
Nature; 2014 Jul; 511(7511):616-20. PubMed ID: 25043025
[TBL] [Abstract][Full Text] [Related]
25. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Chipumuro E; Marco E; Christensen CL; Kwiatkowski N; Zhang T; Hatheway CM; Abraham BJ; Sharma B; Yeung C; Altabef A; Perez-Atayde A; Wong KK; Yuan GC; Gray NS; Young RA; George RE
Cell; 2014 Nov; 159(5):1126-1139. PubMed ID: 25416950
[TBL] [Abstract][Full Text] [Related]
26. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
[TBL] [Abstract][Full Text] [Related]
27. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
Yuan J; Jiang YY; Mayakonda A; Huang M; Ding LW; Lin H; Yu F; Lu Y; Loh TKS; Chow M; Savage S; Tyner JW; Lin DC; Koeffler HP
Cancer Res; 2017 Dec; 77(23):6614-6626. PubMed ID: 28951465
[TBL] [Abstract][Full Text] [Related]
28. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
[TBL] [Abstract][Full Text] [Related]
29. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
30. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
[TBL] [Abstract][Full Text] [Related]
31. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.
Attia YM; Shouman SA; Salama SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340192
[TBL] [Abstract][Full Text] [Related]
32. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
33. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
[TBL] [Abstract][Full Text] [Related]
34. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
35. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
36. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
37. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
38. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract][Full Text] [Related]
39. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
[TBL] [Abstract][Full Text] [Related]
40. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
Delehouzé C; Godl K; Loaëc N; Bruyère C; Desban N; Oumata N; Galons H; Roumeliotis TI; Giannopoulou EG; Grenet J; Twitchell D; Lahti J; Mouchet N; Galibert MD; Garbis SD; Meijer L
Oncogene; 2014 Dec; 33(50):5675-87. PubMed ID: 24317512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]